Results 211 to 220 of about 205,719 (255)

Beyond the KRAS test

European Journal of Cancer, 2009
The anti-epidermal growth factor receptor (EGFR) antibodies cetuximab and panitumumab have been demonstrated to be efficient in the treatment of irinotecan-resistant and chemorefractory metastatic colorectal cancer (mCRC) respectively. However, these costly and potentially toxic treatments are only efficient in a small proportion of patients.
Pierre, Laurent-Puig, Astrid, Lièvre, Hélène, Blons   +2 more
openaire   +2 more sources

KRAS mutations: Analytical considerations

Clinica Chimica Acta, 2014
Colorectal cancer (CRC) is the third most common cancer and the second most common cause of cancer death globally. Significant improvements in survival have been made in patients with metastasis by new therapies. For example, Cetuximab and Panitumumab are monoclonal antibodies that inhibit the epidermal growth receptor (EGFR).
Marta Herreros-Villanueva, Chih-Chieh Chen, Shyng-Shiou F. Yuan, Ta-Chih Liu, Tze-Kiong Er   +4 more
openaire   +2 more sources

KRAS inhibitors, approved

Nature Cancer, 2021
Rafael Rosell, Andrés Aguilar, Carlos Pedraz, Imane Chaib   +3 more
openaire   +2 more sources

KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma

Molecular Cancer Therapeutics
Abstract Pancreatic ductal adenocarcinoma (PDAC) is associated with significant morbidity and mortality and is projected to be the second leading cause of cancer-related deaths by 2030. Mutations in KRAS are found in the vast majority of PDAC cases and plays an important role in the development of the disease.
Minh T. Than, Mark O’Hara, Ben Z. Stanger, Kim A. Reiss   +3 more
openaire   +2 more sources

KRAS

2020
Daniela Furlan, Nora Sahnane
openaire   +1 more source

Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment

Nature Reviews Cancer, 2021
Samuel Andrew Kerk, Thales Papagiannakopoulos, Yatrik M Shah   +2 more
exaly  

KRAS mutation: from undruggable to druggable in cancer

Signal Transduction and Targeted Therapy, 2021
Liwu Fu
exaly  

KRA

2021
openaire   +1 more source

Advances in covalent drug discovery

Nature Reviews Drug Discovery, 2022
Lydia Boike, Nathaniel Henning, Daniel K Nomura   +2 more
exaly